ABSTRACT
The aim of this study was to determine IDDM incidence in the Metropolitan Region of Chile, during the period 1990-1993 as part of the Multinational Project for Childhood Diabetes (WHO DIAMOND project group). The studied population was 1.499.784 inhabitants. All children in whom the diagnosis was made between january 1, 1990 and dec. 31, 1993 were included. We used a retrospective and prospective search and confirmation method, using as data sources public and private hospitals and medical records of pediatricians. The juvenile Diabetes Foundation was used as a secondary data source. All cases had at least two confirmation sources. A total of 176 new cases (90 males) were diagnosed in the study period, with an annual incidence of 2.92/100,000 for females and 2.95 for males. The group of children from 10 to 14 years old had the highest incidence rate (4.9/100.000), specially in women (5.25/100.000). The yearly incidence was 1.31 in 1990, 2.71 in 1991, 2.93 in 1992 and 3.7/1000,000 in 1993). It is concluded that the Metropolitan Region has one of the lowest incidences of IDDM in Latin America, although it increased along the study years
Subject(s)
Humans , Male , Female , Child, Preschool , Adolescent , Diabetes Mellitus, Type 1/epidemiology , Cross-Sectional Studies , Age Distribution , Sex DistributionABSTRACT
Se presenta una casuística de 54 pacientes con impotencia por disfunción eréctil estudiados en el policlínico de urología del Hospital San Juan de Dios. En ellos destacan algunas patologías concomitantes tales como diabetes (48 por ciento) e hipertensión arterial (24 por ciento) y factores asociados eventualmente relacionados con la impotencia tales como consumo de ciertos medicamentos (30 por ciento); alcoholismo (16 por ciento) y tabaquismo (16 por ciento). El 73 por ciento de los pacientes respondieron a la administración de papaverina, lo que sugiere la participación de factores psicogénicos asociados a alteraciones vasculares leves o moderadas. Pese a los buenos resultados observados sólo el 34 por ciento de los respondedores aceptaron continuar con autoinyecciones de papaverina